Metabolic Therapy Program In Conjunction With Standard Treatment For Glioblastoma
Glioblastoma
About this trial
This is an interventional treatment trial for Glioblastoma focused on measuring cancer, glioblastoma, metabolic therapy, fasting, ketogenic diet
Eligibility Criteria
Inclusion Criteria:
- Age 18 years or greater.
- Newly-diagnosed histologically-confirmed GBM.
- ECOG Performance Status 0-2.
- Planned for standard chemoradiation for GBM.
- If receiving dexamethasone, the dose must be ≤ 4 mg daily (and not increasing) upon commencement of the MTP.
Exclusion Criteria:
- Ineligible for standard treatment for GBM due to poor performance status, co-morbidities, or inability to give informed consent.
- Type 1 diabetes.
- A medical or psychiatric disorder that, in the opinion of the investigators, would make it unlikely that the patient could adhere to the MTP.
Sites / Locations
- Waikato HospitalRecruiting
Arms of the Study
Arm 1
Experimental
Standard treatment in conjunction with MTP
Standard: Concurrent chemoradiation - Radiation (60-Gy in 30 fractions over 6 weeks) with daily oral temozolomide. Adjuvant chemotherapy - Daily oral temozolomide (5 days per 4-week cycle, starting 4 weeks after completion of chemoradiation, with at least 6 cycles intended). MTP: - Two 5-day fasts (allowing water, salt, tea, coffee, and a magnesium supplement) during chemoradiation followed by a 5-day fast during each adjuvant chemotherapy cycle, with a time-restricted modified ketogenic diet (one or two 1-hour eating windows per day, allowing oils, meats, vegetables, nuts, seeds, limited berries, and a multivitamin) between fasts.